Disease · MONDO_0001718
scleritis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. scleritis. Diseases, record MONDO_0001718. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001718
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| INFLIXIMAB | CHEMBL1201581 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CORTICOTROPIN | CHEMBL1201610 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TOFACITINIB | CHEMBL221959 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXAMETHASONE PHOSPHORIC ACID | CHEMBL1201302 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PSI-697 | CHEMBL219046 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| JAK1 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| MC2R | Adrenocorticotropic hormone receptor | 1 | Melanocortin receptor 2 agonist | Phase 2 | https://conductscience.org/library/genes/4158 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 1 | B-lymphocyte antigen CD20 binding agent | Phase 1/2 | https://conductscience.org/library/genes/931 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 1 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| TNF | Tumor necrosis factor | 1 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 2 | https://conductscience.org/library/genes/7297 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00415506 | Rituximab in the Treatment of Scleritis and Non-Infectious Orbital Inflammation | Phase 1/2 | 20 | 2013-08-08 | Scleritis, Orbital Disease | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03580343 | Tofacitinib for Inflammatory Eye Disease | Phase 2 | 5 | 2021-02-01 | Uveitis, Scleritis | TOFACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03465111 | A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis | Phase 2 | 30 | Scleritis | CORTICOTROPIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01059955 | Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study | Phase 1 | 18 | Non-infectious, Non-necrotizing Anterior Scleritis | DEXAMETHASONE PHOSPHORIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT00367692 | Study Evaluating PSI-697 in Patients With Scleritis | Phase 1 | 12 | Scleritis | PSI-697 | Its record names the disease | ClinicalTrials.gov | |
| NCT00075075 | Infliximab to Treat Non-Infectious Scleritis | Phase 1 | 5 | Scleritis | INFLIXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT03088293 | Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS) | Phase 3 | 0 | Idiopathic Refractory Scleritis | CYCLOPHOSPHAMIDE, INFLIXIMAB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Scleritis vs Orbital Inflammation: Improved Control of Inflammation | 9 of 12 | 7 of 10 | 22 | NCT00415506 | Trial comparisons |
| Orbital Inflammation vs Scleritis: serious adverse events | 0 of 10 | 0 of 12 | 22 | NCT00415506 | Trial comparisons |
| Scleritis vs Orbital Inflammation: Reduction of Medications | 5 of 11 | 4 of 6 | 17 | NCT00415506 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001718
GET https://conductscience.org/api/diseases/v1/MONDO_0001718/drugs